Sanara MedTech (NASDAQ:SMTI) Stock Price Expected to Rise, HC Wainwright Analyst Says

Sanara MedTech (NASDAQ:SMTI) had its price target boosted by HC Wainwright from $51.00 to $53.00 in a research report sent to investors on Thursday,Benzinga reports. They currently have a buy rating on the stock. HC Wainwright also issued estimates for Sanara MedTech’s FY2026 earnings at ($1.13) EPS.

Separately, Cantor Fitzgerald reiterated an “overweight” rating and issued a $46.00 target price on shares of Sanara MedTech in a report on Wednesday, March 26th.

Sanara MedTech Trading Up 2.0%

NASDAQ:SMTI opened at $31.50 on Thursday. The firm has a fifty day simple moving average of $31.06 and a two-hundred day simple moving average of $33.45. Sanara MedTech has a 12 month low of $25.86 and a 12 month high of $39.08. The stock has a market capitalization of $279.97 million, a price-to-earnings ratio of -31.82 and a beta of 1.38. The company has a current ratio of 2.23, a quick ratio of 2.02 and a debt-to-equity ratio of 0.76.

Sanara MedTech (NASDAQ:SMTI) last issued its earnings results on Wednesday, May 14th. The company reported ($0.41) EPS for the quarter, missing analysts’ consensus estimates of ($0.31) by ($0.10). The firm had revenue of $23.43 million during the quarter, compared to the consensus estimate of $23.48 million. Sanara MedTech had a negative net margin of 10.71% and a negative return on equity of 19.86%. Analysts expect that Sanara MedTech will post -1.1 EPS for the current fiscal year.

Institutional Investors Weigh In On Sanara MedTech

Several hedge funds and other institutional investors have recently made changes to their positions in the business. GAMMA Investing LLC boosted its stake in Sanara MedTech by 8,423.8% during the 1st quarter. GAMMA Investing LLC now owns 1,790 shares of the company’s stock valued at $58,000 after purchasing an additional 1,769 shares during the last quarter. Wells Fargo & Company MN boosted its position in shares of Sanara MedTech by 53.9% during the fourth quarter. Wells Fargo & Company MN now owns 1,893 shares of the company’s stock valued at $63,000 after buying an additional 663 shares during the last quarter. MetLife Investment Management LLC bought a new stake in Sanara MedTech during the first quarter worth $82,000. BNP Paribas Financial Markets bought a new stake in Sanara MedTech during the fourth quarter worth $106,000. Finally, Rhumbline Advisers raised its position in Sanara MedTech by 14.9% in the 1st quarter. Rhumbline Advisers now owns 3,714 shares of the company’s stock valued at $115,000 after buying an additional 483 shares during the last quarter. 8.10% of the stock is owned by institutional investors.

Sanara MedTech Company Profile

Sanara MedTech Inc, a medical technology company, develops, markets, and distributes surgical, wound, and skincare products and services to physicians, hospitals, clinics, and post-acute care settings in the United States. The company offers CellerateRX Surgical, a medical hydrolysate of Type I bovine collagen indicated for the management of surgical, traumatic, and partial- and full-thickness wounds, as well as first- and second-degree burns; and HYCOL, a medical hydrolysate of Type I bovine collagen intended for the management of full and partial thickness wounds, including pressure ulcers, venous and arterial leg ulcers, and diabetic foot ulcers.